Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus

Spottke, EA; Volkmann, Jens; Lorenz, Delia; Krack, Paul; Smala, Antje; Sturm, Volker; Gerstner, A.; Berger, Karin; Hellwig, Dieter; Deuschl, Günther; Freund, Hans‐Joachim; Oertel, Wolfgang H.; Dodel, Richard

doi:10.1007/s00415-002-0711-7

Cited by 70 publications

(63 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study showed STN-DBS anti-parkinsonian clinical efficacy and that costeffectiveness is directly related to clinical improvement in parkinsonism and to the reduction of pharmacological expenses after the intervention. As shown by others (Charles et al, 2004;Fraix et al, 2006;Meissner et al, 2005;Spottke et al, 2002), this survey in the Spanish setting showed that STN-DBS is within the adequate limits to be considered as an efficient therapy. Considering the published data available in the literature assessing DBS for APD, it can be considered safe, effective and cost-effective compared with BMT.…”

Section: Cost-effectiveness Of Bilateral Subthalamic Stimulation In Asupporting

confidence: 60%

“…A multicentric French survey (Fraix et al, 2006) observed similar improvement of UPDRS scores and decrement of PD costs. In another survey, a prospective analysis, the incremental cost per total UPDRS unit improvement turned out to be €920 (Spottke et al, 2002). Some studies have included the cost of the battery replacement after five years of use (D'Ausilio et al, 2003;McIntosh et al, 2003;Tomaszewski & Holloway, 2001).…”

Section: Cost-effectiveness Of Bilateral Subthalamic Stimulation In Amentioning

confidence: 99%

See 1 more Smart Citation

Cost and Efficacy of Therapies for Advanced Parkinson's Disease

Valldeoriola¹

2011

Towards New Therapies for Parkinson's Disease

View full text Add to dashboard Cite

Section: Cost-effectiveness Of Bilateral Subthalamic Stimulation In Asupporting

confidence: 60%

Section: Cost-effectiveness Of Bilateral Subthalamic Stimulation In Amentioning

confidence: 99%

Cost and Efficacy of Therapies for Advanced Parkinson's Disease

Valldeoriola¹

2011

Towards New Therapies for Parkinson's Disease

View full text Add to dashboard Cite

“…The role of national health care programs for PD patients that receive neurosurgical treatment has been a successful one in high-income countries. The awareness of decision makers in these countries that movement disorder surgery needs to rely on public health care systems reinforces this policy [8]. Fewer procedures per patient were observed when patients were operated on under a public health care system, compared to the number of procedures financed by private insurance, or those that the patients paid for themselves.…”

Section: Discussionmentioning

confidence: 99%

Health Economics and Surgical Treatment for Parkinson's Disease in a World Perspective: Results from an International Survey

Jourdain

Schechtmann²

2014

Stereotact Funct Neurosurg

View full text Add to dashboard Cite

Background: Most studies in the field of neurosurgical treatment for movement disorders have been published by a small number of leading centers in developed countries. This study aimed to investigate the clinical practice of stereotactic neurosurgery for Parkinson's disease (PD) worldwide. Methods: Neurosurgeons were contacted via e-mail to participate in a worldwide survey. The results obtained are presented in order of the countries' economic development according to the World Bank, as well as by the source of financial support. Results: A total of 353 neurosurgeons from 51 countries who had operated on 13,200 patients in 2009 were surveyed. Surgical procedures performed in high-income countries were more commonly financed by a public health care system. In contrast, in lower-middle-income and upper-middle-income countries, patients frequently financed surgeries themselves, and ablative surgeries were most commonly performed. Unexpectedly, ablative surgery is still used by about 65% of neurosurgeons, regardless of their country's economic status. Conclusions: This study provides a previously unavailable picture of the surgical aspects of PD across the globe in relation to health economics and sociodemographic factors. Global educational and training programs are warranted to raise awareness of economically viable surgical options for PD that could be adopted by public health care systems in lower-income countries.

show abstract

“…Furthermore, it was assumed that approximately a third of the patients who develop significant graft-induced dyskinesias would require additional neurosurgery. The cost of such additional surgery was estimated to €20 000 [23]. The remaining two-thirds of dyskinetic patients were assumed to receive treatment with amantadine, estimated to an annual cost of €540 (the cost of a daily dose of 200 mg amantadine in Sweden).…”

Section: Model Applicationmentioning

confidence: 99%

Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement

Hjelmgren¹,

Ghatnekar²,

Reimer³

et al. 2006

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

A long-term cost-effectiveness model for early decision-making and estimation of outcomes of novel therapeutic procedures for Parkinson's disease (PD) was developed based on the Hoehn and Yahr (HY) stages of PD. Results provided support for model validity. Model application to a future dopamine cell replacement therapy indicated long-term cost offsets and gains in quality-adjusted life years in early onset PD (HY III-IV), as compared to standard drug therapy. The maximum price premium (i.e., profit or compensation for developmental costs) for the intervention to remain cost-effective was estimated to €12 000-€64 000 according to cost-per-QALY thresholds of €38 000-€70 000 and depending on whether all or only medical direct costs are considered. The study illustrates the value of early health economic modeling and the described model shows promise as a means to estimate outcomes and aid decision-making regarding novel interventions for PD.3

show abstract

Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus

Cited by 70 publications

References 18 publications

Cost and Efficacy of Therapies for Advanced Parkinson's Disease

Cost and Efficacy of Therapies for Advanced Parkinson's Disease

Health Economics and Surgical Treatment for Parkinson's Disease in a World Perspective: Results from an International Survey

Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement

Contact Info

Product

Resources

About